China Unveils Detailed Rules to Implement the Core Device Regulation

by Ropes & Gray LLP

The amended Regulation for the Supervision and Administration of Medical Devices (the “Regulation,” also known as the State Council Order No. 650), which came into force on June 1, 2014, set the new framework for China’s device regulatory regime. On August 1, 2014, the China Food and Drug Administration (the “CFDA”) unveiled five rules to implement this core Regulation (the “Implementing Rules”). The Implementing Rules cover several key aspects of regulating medical devices, including marketing authorization, package inserts and labelling requirements, manufacturing, distribution, and separate rules for IVD products. The most noteworthy updates include the following:

  • Contract manufacturing of prototypes and commercial supplies is only available for innovative devices.

    According to the Regulation, companies may apply for marketing authorizations (or product registrations) without first obtaining device manufacturing permits. 

    The Implementing Rules clarify that a company will still need a manufacturing permit to commercialize the product license if its product is not an innovative device designated for fast track approval by the CFDA. Only license owners of CFDA-designated innovative devices can completely outsource manufacturing of both the initial prototype and the final commercial supplies, with the exception of certain high-risk implantable devices. In the event where the product in question is a non-innovative device, the license owner must manufacture a prototype in its own capacity, build its own manufacturing facilities and obtain a device manufacturing permit before it can use a contract manufacturer for the unmet manufacturing demands. 

  • Clinical trial waiver is possible if safety and efficacy can be demonstrated through analysis of clinical data of the same type of products.

    The Regulation generally requires companies to conduct clinical trials for the registration of Class II and III devices unless certain prerequisites are met. It also provides that a “waiver catalogue” will be issued by the CFDA to list all the exempted devices. It left open whether a product not on the “waiver catalogue” can be waived from clinical trials.

    Now the Implementing Rules clarify that for products not on the “waiver catalogue,” an applicant can still apply for trial waiver on a case-by-case basis. To obtain a waiver, an applicant must demonstrate the safety and efficacy of a device through data derived from clinical trials or clinical uses of the same type of product. 

    For certain high-risk Class III devices, the Regulation also requires clinical trial authorizations (“CTA”) before conducting clinical trials. The Implementing Rules further specify that the technical review of a CTA should be completed within 40 working days of submission, and the trials should be initiated within three years of the issuance of a CTA.

  • Mandatory QMS/GMP on-site inspections will be arranged before product registration and manufacturing authorization.

    The Regulation generally requires that companies comply with the relevant quality management requirements during product design and development. It is not clear whether an actual inspection over the applicant’s quality management system (QMS/ GMP) would be conducted by the provincial FDAs during the product registration stage.

    The Implementing Rules clarify that during the technical review of a domestic product, the relevant provincial FDA is responsible for organizing a QMS/GMP inspection of the applicant, to be completed within 30 working days. This additional step could potentially prolong the device registration process. It is speculated that a later QMS/GMP inspection prior to the grant of the manufacturing permit may take less time.

    As for import products, overseas QMS/GMP inspections can also be carried out by the CFDA over foreign applicants when deemed necessary during the technical review.

  • License amendment for non-substantive changes and license renewal are simplified.

    The Implementing Rules divide a product license amendment into an amendment of either “approved items” or “registered items.” Changes to “approved items” — such as product name, model, specifications, structure and composition, scope of use, and product technical standards — will require technical reviews and longer lead time. Changes to “registered items,” on the other hand, such as the name and address of the applicant, can be granted within 10 working days of submission.

    In any case, a product license is now valid for five years and renewal cannot be rejected except on explicit statutory grounds. If a renewal application is neither approved nor rejected on the date of license expiry, renewal is deemed automatic.

Device companies are encouraged to carefully review the Implementing Rules in conjunction with the Regulation and assess the potential impact on their market access and regulatory compliance in China. Meanwhile, the CFDA is contemplating more ancillary device rules, including a new version of device classification, a new GSP and an updated GMP in the coming months and stakeholders should continue to monitor the progress.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ropes & Gray LLP | Attorney Advertising

Written by:

Ropes & Gray LLP

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.